NCT01680952 is a Phase 4 clinical trial of A) TEST in Kidney Transplant Patients, sponsored by Yonsei University.

Who is sponsoring NCT01680952?

NCT01680952 is sponsored by Yonsei University.

What drugs are being tested in NCT01680952?

Interventions in NCT01680952: A) TEST, B) CONTROL.

What condition does NCT01680952 study?

NCT01680952 studies Kidney Transplant Patients.

Is NCT01680952 still recruiting?

NCT01680952 is currently completed. Last updated 7 March 2016.

Last reviewed 2016-03-07 · How we verify

NCT01680952

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients

Completed Phase 4 Last updated 7 March 2016

What this trial tests

Phase 4 trial testing A) TEST in Kidney Transplant Patients in 158 participants. Completed in 1 January 2016.

Timeline

1 September 2012

Primary endpoint
1 January 2016

1 January 2016

Quick facts

Lead sponsor	Yonsei University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	158
Start date	1 September 2012
Primary completion	1 January 2016
Estimated completion	1 January 2016
Sites	7 locations across South Korea

Drugs / interventions tested

A) TEST — full drug profile →
B) CONTROL

Conditions studied

Kidney Transplant Patients — all drugs for Kidney Transplant Patients →

Sponsor

Yonsei University

Who can join

20 and older, any sex, with Kidney Transplant Patients. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Failure rate in effectiveness of up to 12 months after kidney transplant
Time frame: 12 months after kidney transplant
1. Biopsy confirmed acute rejection 2. Subjects and graft survival 3. Glomerular filtration rate (GFR) 4. 24-hour urine test results at 12 months after kidney transplant: Urine protein, CrCl.

Sponsor's own description

This study will compare the efficacy and safety of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate mofetil in Kidney Transplant Patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
Huh KH, Lee JG, Ha J, Oh CK, et al · · 2017 · cited 16× · PMID 28810721 · DOI 10.1093/ndt/gfx093

Verify or expand the search:

Other recruiting trials for Kidney Transplant Patients

Currently open trials in the same condition.

NCT05039788 — Observational Single-center Study of the Relationship Between Arterial Hypertension and Hypervolemia Defined by Self-mea · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01680952 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 7 March 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01680952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing